

# Frank Porreca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2121882/publications.pdf>

Version: 2024-02-01

105  
papers

4,868  
citations

109264

35  
h-index

110317

64  
g-index

106  
all docs

106  
docs citations

106  
times ranked

5194  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. <i>Brain</i> , 2023, 146, 1186-1199.	3.7	8
2	A prolactin-dependent sexually dimorphic mechanism of migraine chronification. <i>Cephalalgia</i> , 2022, 42, 197-208.	1.8	14
3	Relief of neuropathic pain by cell-specific manipulation of nucleus accumbens dopamine D1- and D2-receptor-expressing neurons. <i>Molecular Brain</i> , 2022, 15, 10.	1.3	14
4	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. <i>Cephalalgia</i> , 2022, , 033310242210998.	1.8	3
5	Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. <i>Cellular and Molecular Neurobiology</i> , 2021, 41, 949-960.	1.7	6
6	Green Light Exposure Improves Pain and Quality of Life in Fibromyalgia Patients: A Preliminary One-Way Crossover Clinical Trial. <i>Pain Medicine</i> , 2021, 22, 118-130.	0.9	26
7	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. <i>Cephalalgia</i> , 2021, 41, 305-317.	1.8	21
8	Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. <i>Cephalalgia</i> , 2021, 41, 135-147.	1.8	29
9	CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. <i>Cephalalgia</i> , 2021, 41, 749-759.	1.8	17
10	The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 278-284.	1.6	97
11	Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors. <i>Neuropharmacology</i> , 2021, 185, 108456.	2.0	25
12	Cognition in the Chronic Pain Experience: Preclinical Insights. <i>Trends in Cognitive Sciences</i> , 2021, 25, 365-376.	4.0	38
13	Multifunctional Enkephalin Analogs with a New Biological Profile: MOR/DOR Agonism and KOR Antagonism. <i>Biomedicines</i> , 2021, 9, 625.	1.4	5
14	Chronic Pain Produces Reversible Memory Deficits That Depend on Task Difficulty in Rats. <i>Journal of Pain</i> , 2021, 22, 1467-1476.	0.7	5
15	A new hypothesis linking oxytocin to menstrual migraine. <i>Headache</i> , 2021, 61, 1051-1059.	1.8	11
16	Introducing descending control of nociception: a measure of diffuse noxious inhibitory controls in conscious animals. <i>Pain</i> , 2021, 162, 1957-1959.	2.0	17
17	Sexual dimorphism in functional pain syndromes. <i>Science Translational Medicine</i> , 2021, 13, eabj7180.	5.8	12
18	Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain. <i>Cell Reports</i> , 2021, 37, 109933.	2.9	27

#	ARTICLE	IF	CITATIONS
19	C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 51, 116509.	1.4	1
20	Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020, 40, 68-78.	1.8	15
21	Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. <i>Pain</i> , 2020, 161, 609-618.	2.0	34
22	An Emerging Role for Prolactin in Female-Selective Pain. <i>Trends in Neurosciences</i> , 2020, 43, 635-648.	4.2	25
23	Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. <i>Cephalalgia</i> , 2020, 40, 1535-1550.	1.8	17
24	Amygdala, neuropeptides, and chronic pain-related affective behaviors. <i>Neuropharmacology</i> , 2020, 170, 108052.	2.0	109
25	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020, 40, 892-902.	1.8	47
26	Impact of chronic migraine attacks and their severity on the endogenous $\mu$ -opioid neurotransmission in the limbic system. <i>NeuroImage: Clinical</i> , 2019, 23, 101905.	1.4	26
27	Post-traumatic headache: epidemiology and pathophysiological insights. <i>Nature Reviews Neurology</i> , 2019, 15, 607-617.	4.9	131
28	CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. <i>Cephalalgia</i> , 2019, 39, 1762-1775.	1.8	66
29	Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1761-1780.	2.9	35
30	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology</i> , The, 2019, 18, 891-902.	4.9	151
31	Opioid analgesics pass the acid test. <i>Lancet</i> , The, 2019, 393, 1579-1581.	6.3	0
32	Inhibition of experimental visceral pain in rodents by cebranopadol. <i>Behavioural Pharmacology</i> , 2019, 30, 320-326.	0.8	6
33	Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light. <i>Journal of Pain</i> , 2019, 20, 1293-1306.	0.7	15
34	Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. <i>Pain</i> , 2019, 160, 824-832.	2.0	75
35	Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously. <i>Neuron</i> , 2019, 101, 353-355.	3.8	42
36	Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. <i>Pain</i> , 2019, 160, 1614-1621.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. <i>Cephalalgia</i> , 2019, 39, 617-625.	1.8	26
38	Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. <i>Molecular Pain</i> , 2018, 14, 174480691875640.	1.0	57
39	Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system. <i>Molecular Pain</i> , 2018, 14, 174480691875493.	1.0	12
40	The opioid crisis and re-considering the use of drugs that affect body temperature. <i>Temperature</i> , 2018, 5, 1-3.	1.6	2
41	Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. <i>Journal of Controlled Release</i> , 2018, 270, 135-144.	4.8	51
42	Kappa Opioid Receptor Distribution and Function in Primary Afferents. <i>Neuron</i> , 2018, 99, 1274-1288.e6.	3.8	100
43	The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. <i>Neuropharmacology</i> , 2018, 141, 260-271.	2.0	13
44	Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. <i>Pain</i> , 2018, 159, 2512-2521.	2.0	46
45	Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3664-3667.	1.4	6
46	Selective deficiencies in descending inhibitory modulation in neuropathic rats: implications for enhancing noradrenergic tone. <i>Pain</i> , 2018, 159, 1887-1899.	2.0	23
47	Engagement of kappa opioid system in the right amygdala diminishes diffuse noxious inhibitory controls (DNIC). <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-2-19.</i>	0.0	0
48	Activation of dura-sensitive trigeminal neurons and increased c-Fos protein induced by morphine withdrawal in the rostral ventromedial medulla. <i>Cephalalgia</i> , 2017, 37, 407-417.	1.8	10
49	Mechanisms of craniofacial pain. <i>Cephalalgia</i> , 2017, 37, 613-626.	1.8	101
50	Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. <i>Pain</i> , 2017, 158, 347-360.	2.0	81
51	Reward, motivation, and emotion of pain and its relief. <i>Pain</i> , 2017, 158, S43-S49.	2.0	119
52	Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1147-1158.	1.7	37
53	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. <i>Cephalalgia</i> , 2017, 37, 780-794.	1.8	70
54	Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. <i>Pain</i> , 2017, 158, 2386-2395.	2.0	74

#	ARTICLE	IF	CITATIONS
55	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. <i>Cephalalgia</i> , 2017, 37, 1350-1372.	1.8	31
56	Various modifications of the amphipathic dynorphin <scp>A</scp> pharmacophore for rat brain bradykinin receptors. <i>Chemical Biology and Drug Design</i> , 2016, 88, 615-619.	1.5	2
57	Positive emotions and brain reward circuits in chronic pain. <i>Journal of Comparative Neurology</i> , 2016, 524, 1646-1652.	0.9	67
58	Cyclic non-opioid dynorphin A analogues for the bradykinin receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5513-5516.	1.0	5
59	Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1746-1752.	1.7	7
60	Structure-Activity Relationships of [des-Arg<sup>7</sup>]Dynorphin A Analogues at the $\mu$ Opioid Receptor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10291-10298.	2.9	11
61	Efficacy of (S)-lacosamide in preclinical models of cephalic pain. <i>Pain Reports</i> , 2016, 1, e565.	1.4	24
62	(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. <i>Pain</i> , 2016, 157, 1448-1463.	2.0	54
63	Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis. <i>Journal of Pain</i> , 2016, 17, 374-382.	0.7	75
64	Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. <i>Pain</i> , 2016, 157, 2731-2738.	2.0	38
65	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. <i>Brain</i> , 2015, 138, 28-35.	3.7	120
66	Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist and Neurokinin-1 antagonist peptidomimetics. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 64-77.	2.6	27
67	Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3716-3720.	1.0	14
68	Endogenous Opioid Activity in the Anterior Cingulate Cortex Is Required for Relief of Pain. <i>Journal of Neuroscience</i> , 2015, 35, 7264-7271.	1.7	154
69	Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4683-4688.	1.0	10
70	Brain Circuits Encoding Reward from Pain Relief. <i>Trends in Neurosciences</i> , 2015, 38, 741-750.	4.2	174
71	Discovery of Novel Multifunctional Ligands with $\mu$ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8573-8583.	2.9	16
72	Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4148-4152.	1.0	4

#	ARTICLE	IF	CITATIONS
73	Discovery of 5-substituted tetrahydronaphthalen-2-yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6185-6194.	1.4	2
74	Modification of amphipathic non-opioid dynorphin A analogues for rat brain bradykinin receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 30-33.	1.0	11
75	Blockade of non-opioid excitatory effects of spinal Dynorphin A at bradykinin receptors. <i>Receptors &amp; Clinical Investigation</i> , 2015, 2, .	0.9	2
76	Lost but making progress—Where will new analgesic drugs come from?. <i>Science Translational Medicine</i> , 2014, 6, 249sr3.	5.8	102
77	Novel Cyclic Biphalin Analogue with Improved Antinociceptive Properties. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1032-1036.	1.3	30
78	Structure–activity relationships of non-opioid [des-Arg7]-dynorphin A analogues for bradykinin receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4976-4979.	1.0	11
79	Reward and motivation in pain and pain relief. <i>Nature Neuroscience</i> , 2014, 17, 1304-1312.	7.1	370
80	The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. <i>Journal of Pain</i> , 2014, 15, 241-249.	0.7	159
81	The development of bifunctional ligands as novel therapeutics for chronic pain (1061.5). <i>FASEB Journal</i> , 2014, 28, 1061.5.	0.2	0
82	Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 92-107.	3.1	64
83	Chiral Effect of a Phe Residue in Position 3 of the Dmt <sup>1</sup> (or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 34 Letters, 2013, 4, 656-659.	1.3	3
84	New potent biphalin analogues containing p-fluoro-l-phenylalanine at the 4,4-positions and non-hydrazine linkers. <i>Amino Acids</i> , 2011, 40, 1503-1511.	1.2	30
85	Triptan–induced latent sensitization: A possible basis for medication overuse headache. <i>Annals of Neurology</i> , 2010, 67, 325-337.	2.8	181
86	Nausea and Vomiting Side Effects with Opioid Analgesics during Treatment of Chronic Pain: Mechanisms, Implications, and Management Options. <i>Pain Medicine</i> , 2009, 10, 654-662.	0.9	175
87	Synthesis and biological activity of the first cyclic biphalin analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 367-372.	1.0	39
88	Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2471-2475.	1.0	25
89	Retrovirus-Mediated Expression of an Artificial $\delta^2$ -Endorphin Precursor in Primary Fibroblasts. <i>Journal of Neurochemistry</i> , 2002, 64, 475-481.	2.1	23
90	?-Azido acids for direct use in solid-phase peptide synthesis. <i>Journal of Peptide Science</i> , 2000, 6, 594-602.	0.8	28

#	ARTICLE	IF	CITATIONS
91	Spinal and Supraspinal Mechanisms of Neuropathic Pain. <i>Annals of the New York Academy of Sciences</i> , 2000, 909, 12-24.	1.8	220
92	Exploring the Structure-Activity Relationships of [1-(4-tert-Butyl-3-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), A High-Affinity and Selective $\mu$ -Opioid Receptor Nonpeptide Agonist Ligand. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5359-5368.	2.9	29
93	Opioid peptide receptor studies. 7. The methylenfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat $\mu$ opioid receptor. <i>Synapse</i> , 1998, 28, 117-124.	0.6	12
94	Orphanin-FQ/nociceptin: Lack of antinociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. <i>European Journal of Pain</i> , 1998, 2, 267-278.	1.4	25
95	De Novo Design, Synthesis, and Biological Activities of High-Affinity and Selective Non-Peptide Agonists of the $\mu$ -Opioid Receptor. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4767-4776.	2.9	67
96	Cyclic Enkephalin Analogues with Exceptional Potency and Selectivity for $\mu$ -Opioid Receptors. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3957-3962.	2.9	42
97	Peptide Targeting and Delivery across the Blood-Brain Barrier Utilizing Synthetic Triglyceride Esters: Design, Synthesis, and Bioactivity. <i>Bioconjugate Chemistry</i> , 1997, 8, 434-441.	1.8	25
98	Synthesis and biological properties of $\mu$ -MePhe <sup>3</sup> analogues of deltorphin I and dermenkephalin: influence of biased X <sup>1</sup> of Phe <sup>3</sup> residues on peptide recognition for $\mu$ -opioid receptors. <i>Chemical Biology and Drug Design</i> , 1997, 50, 48-54.	1.2	15
99	Effects of Modifications of Residues in Position 3 of Dynorphin A(1-11)-NH <sub>2</sub> on $\mu$ Receptor Selectivity and Potency. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2456-2460.	2.9	31
100	Design, Synthesis, and Biological Activities of Cyclic Lactam Peptide Analogues of Dynorphin A(1-11)-NH <sub>2</sub> . <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1136-1141.	2.9	31
101	Conformational restriction of Tyr and Phe side chains in opioid peptides: Information about preferred and bioactive side-chain topology. , 1996, 38, 1-12.		73
102	Delta opioid receptor selective ligands; DPLPE-deltorphin chimeric peptide analogues. <i>International Journal of Peptide and Protein Research</i> , 1994, 44, 80-84.	0.1	8
103	Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10. <i>International Journal of Peptide and Protein Research</i> , 1993, 42, 411-419.	0.1	32
104	Development of delta opioid peptides as nonaddicting analgesics. <i>Pharmaceutical Research</i> , 1991, 08, 1-8.	1.7	105
105	Interaction of $\mu$ -funtrexamine with [3H]cycloFOXY binding in rat brain: Further evidence that $\mu$ -FNA alkylates the opioid receptor complex. <i>Synapse</i> , 1991, 8, 86-99.	0.6	22